Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia

No specific therapy is available for COVID-19. We report the effectiveness and adverse effects of triple therapy with hydroxychloroquine, azithromycin, and ciclesonide in patients with COVID-19 pneumonia. The clinical condition of the patients improved within 5 days in response to the therapy.

Detalles Bibliográficos
Autores principales: Mori, Nobuaki, Katayama, Mitsuya, Nukaga, Shigenari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534751/
https://www.ncbi.nlm.nih.gov/pubmed/33054978
http://dx.doi.org/10.1016/j.jmii.2020.09.003
_version_ 1783590361860407296
author Mori, Nobuaki
Katayama, Mitsuya
Nukaga, Shigenari
author_facet Mori, Nobuaki
Katayama, Mitsuya
Nukaga, Shigenari
author_sort Mori, Nobuaki
collection PubMed
description No specific therapy is available for COVID-19. We report the effectiveness and adverse effects of triple therapy with hydroxychloroquine, azithromycin, and ciclesonide in patients with COVID-19 pneumonia. The clinical condition of the patients improved within 5 days in response to the therapy.
format Online
Article
Text
id pubmed-7534751
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.
record_format MEDLINE/PubMed
spelling pubmed-75347512020-10-06 Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia Mori, Nobuaki Katayama, Mitsuya Nukaga, Shigenari J Microbiol Immunol Infect Short Communication No specific therapy is available for COVID-19. We report the effectiveness and adverse effects of triple therapy with hydroxychloroquine, azithromycin, and ciclesonide in patients with COVID-19 pneumonia. The clinical condition of the patients improved within 5 days in response to the therapy. Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. 2021-02 2020-10-05 /pmc/articles/PMC7534751/ /pubmed/33054978 http://dx.doi.org/10.1016/j.jmii.2020.09.003 Text en © 2020 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Short Communication
Mori, Nobuaki
Katayama, Mitsuya
Nukaga, Shigenari
Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia
title Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia
title_full Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia
title_fullStr Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia
title_full_unstemmed Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia
title_short Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia
title_sort triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for covid-19 pneumonia
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534751/
https://www.ncbi.nlm.nih.gov/pubmed/33054978
http://dx.doi.org/10.1016/j.jmii.2020.09.003
work_keys_str_mv AT morinobuaki tripletherapywithhydroxychloroquineazithromycinandciclesonideforcovid19pneumonia
AT katayamamitsuya tripletherapywithhydroxychloroquineazithromycinandciclesonideforcovid19pneumonia
AT nukagashigenari tripletherapywithhydroxychloroquineazithromycinandciclesonideforcovid19pneumonia

Ejemplares similares